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Abstract
Background: Follicular dendritic cell (FDC) sarcoma is a rare neoplasm arising in lymph nodes but
also in extranodal sites from accessory cells of the immune system that are essential for the
function of antigen presentation and germinal center reaction regulation. FDC sarcoma has a
significant recurrent and metastatic potential and for these reason it should be viewed as an
intermediate grade malignancy.
Methods: We report the case of a 49-year old woman patient who showed persistent, enlarged,
hard, cervical lymph node. The most common histologic feature was the presence of oval to spindle
cells with elongated nuclei, vesicular or stippled chromatin and scant eosinophilic cytoplasm.
Immunohistochemically, tumor cells were diffusely positive for follicular dendritic cell markers
CD21, CD23 and negative for cytokeratin.
The patient after complete excision of the lymph node underwent five courses of adjuvant
chemotherapy with COP plus PEG-liposomal doxorubicin, considering the propensity of the tumor
to metastasize.
Results:  No hematological or cardiac toxicity were registered and among the other extra
hematological effects only transitory palmar erythrodysesthesia is worthy of mention. After a
follow up of 5 years the patient is alive and in CR.
Conclusion: These results suggest that this therapeutic modality may be useful in the management
of FDC sarcoma.
Background
Follicular dendritic cell sarcoma is a rare tumor arising
from antigen-presenting cells of the B-cell follicles of
nodal and extranodal sites; these cells are important for
germinal center reaction regulation. It was first described
in 1986 by Monda et al [1] and in recent years there has
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been an increasing interest in this neoplasm due to avail-
ability of specific antibodies to confirm FDC lineage and
thus wider recognition.
Almost all patients have been adults, with a median age of
40 years and with a slight female predominance [2]. Most
patients present with cervical or axillary lymphoadenopa-
thy but extranodal sites, including oral cavity, tonsil, gas-
trointestinal tract, soft tissue [3] and breast, may occur in
almost one third of the patients.
We report a case of nodal FDC sarcoma who was success-
fully diagnosed and treated with surgery and chemother-
apy, comprehending PEG-liposomal doxorubicin.
Methods
A 49 year old woman presented at our Institute with an
enlarged (2 cm), hard, mobile lymph node of the right
cervical area that had been present for about 3 months.
An ultrasound examination of the thyroid gland showed
two nodules of 12 × 8 mm and 6 × 6 mm and a fine needle
aspiration cytology was benign. The patient underwent a
right neck dissection with complete excision of lymph
node and multiple biopsies of nasopharynx, pyriform
sinus and postcricoid area.
The fiberlaryngoscopic and oralpharyngealscopic evalua-
tions were negative for extensive or focal malignancies.
Histopathologic findings
The 2 cm lymph node was partially substituted from a
proliferation of oval-to-spindle cells with vesicular or stip-
pled chromatin and oval to spindle shaped nuclei. The
cells had scant eosinophilic cytoplasm with indistinct bor-
der and the mitotic rate was low (Figure 1).
The follicular areas of lymph node were disappeared but
residual T lymphoid tissue was generally present. Immu-
nologically, the tumor cells showed a close resemblance
to the normal follicular dendritic cells with consistent
expression of CD21 [C3d complement receptor] (Figure
2) and CD23 (Figure 3). Tumor cells were negative for
cytokeratin, CD45, CD20, CD3, CD30, CD68, CD35 and
CD1a; Ki-67 was positive in about 15% of the cells. The
final diagnosis was a follicular dendritic cell sarcoma.
Other tissue specimens from nasopharynx, pyriform sinus
and postcricoid area were free from malignant involve-
ment.
Clinical data
Routine hematological parameters showed hemoglobin
13.1 g/dl, WBC 5.9 × 109/l (53% polymorphonuclear
cells, 39% lymphocytes, 8% monocytes), platelets 214 ×
109/l, all the other biochemical parameters were normal.
Hepatitis B and C, HIV serology were negative, EBV serol-
ogy showed no IgM antibodies but positivity for IgG anti
VCA and IgG anti EBNA.
Bone marrow aspiration and trephine yielded a normal
hemopoiesis. A total body computed scan was made
showing multiple hepatic angiomas (confirmed by MRI
scan) and small subpleural fibrocalcific residuals, the rest
of the exploration was normal. The patient also under-
went an echocardiography that disclosed a good cardiac
function with normal ejection fraction.
Partial substitution of lymph node from a proliferation of  oval-to-spindle cells with vesicular or stippled chromatin,  elongated nuclei, scant eosinophilic cytoplasm and with low  mitotic rate Figure 1
Partial substitution of lymph node from a prolifera-
tion of oval-to-spindle cells with vesicular or stippled 
chromatin, elongated nuclei, scant eosinophilic cyto-
plasm and with low mitotic rate. H&E, × 400.
Immunohistochemical staining: Positive staining for CD21 Figure 2
Immunohistochemical staining: Positive staining for 
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Postoperative adjuvant chemotherapy was administered;
the patient received five courses of COP+PEG-liposomal
doxorubicin according to the following schedule: Cyclo-
phosphamide 750 mg/m2 i.v. (day 1), Vincristine 1.4 mg/
m2 (day 1), PEG-liposomal doxorubicin (Caelyx) 40 mg/
m2 i.v (day 1) and Prednisone 100 mg po days 1–5, every
3 weeks.
Results
No hematological toxicity was reported, but WHO grade
3 skin toxicity was observed. In particular the patient after
the fourth cycle developped a palmar erytrodysesthesia
with painful erytema that was attributed to PEG-lipo-
somal doxorubicin and consequently we reduced at 70%
the dose of Caelyx in the last course of treatment. The ery-
trodysesthesia was transitory and successful treated with
mild dose of prednisone per os.
A total body CT scan performed one month after the last
course of chemotherapy was negative for lymphoaden-
ophaty (Figure 4) and previous subpleural fibrosis was
not modified. Three months after chemotherapy, the
patient also underwent total body 18-F-FDG PET/CT that
showed no residual tumor activity (Figure 5). The patient
is disease free at 5 years after the diagnosis with CT scan
negative.
Discussion
Follicular dendritic cell sarcoma is a rare neoplasm that
can involve lymph nodes or extranodal sites [2,4,5]. Once
FDC sarcoma is suspected from the histologic findings,
immunohistochemical stains for follicular cell differenti-
ation must be performed to avoid the potential for misdi-
agnosis. CD21 and CD35, directed respectively against the
C3d and C3b receptors, together with CD23 and clusterin
Positive staining for CD23 Figure 3
Positive staining for CD23
Cervical region CT scan, one month after chemotherapy,  negative for residual mass  Figure 4
Cervical region CT scan, one month after chemo-
therapy, negative for residual mass
Total body 18-FDG PET three months after chemotherapy,  showing no residual tumor activity  Figure 5
Total body 18-FDG PET three months after chemo-
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are the most widely used markers, demonstrating follicu-
lar dendritic cells differentiation and should help in their
recognition [2,6-9].
FDC sarcoma was considered an indolent tumor with low
tendency of recurrence or metastasis; but recent larger
reports with longer follow up have showed that FDC sar-
coma is more aggressive tumor and should be considered
an intermediate-grade malignancy. Chan et al. have
reported that at least 40% of documented FDC sarcomas
have recurred and 25% have metastasized with a mortality
rate of 16.7% [2,10].
Because this significant recurrent and metastatic potential
it is reasonable that resected localized disease may be pre-
vented from recurrence by adjuvant radiotherapy or
chemotherapy [11-13].
In our case report, the patient underwent surgical excision
and postoperatively was given five cycles of COP plus Cae-
lyx, utilizing cyclophosphamide, vincritine, prednisone
and pegylated liposomal doxorubicin.
PEG liposomal doxorubicin is an alternative preparation
of doxorubicin, which has been shown to have reduced
cardiotoxicity and is characterized by a very long circula-
tion half-life, favorable pharmacokinetic behaviour and
specific accumulation tumor tissues [14,15]. PEG lipo-
somal doxorubicin has already shown activity in soft-tis-
sue sarcoma, head and neck cancer, multiple myeloma,
aggressive non-Hodgkin's lymphoma.
Based on these encouraging experiences and in considera-
tion of the higher response rate, shorter time to response
and less toxicity obtained with PEG liposomal doxoru-
bicin also in the treatment of AIDS-related Kaposi's sar-
coma [16], compared with conventional doxorubicin, we
decided to treat our patient with COP plus Caelyx regi-
men, even if she had no particular cardiac risk. No hema-
tological or cardiac toxicity was registered and among the
other extra hematological effects only palmar erythrodys-
esthesia was worthy of mention. The patient is alive and
event free at 5 years after diagnosis.
In the literature treatment modality of FDC sarcoma var-
ied widely although surgical resection was often included.
With a median follow up of 18 months, about 40% of the
cases recurred and the 5 years recurrence-free survival was
27.4%, further the role of chemotherapy and radiotherapy
in the treatment of this neoplasm is not yet clearly defined
[2,10]. Clinical findings, histology and immunopheno-
type of our case appear to be typical of FDC sarcoma but
the complete resection achieved by surgery and the use of
adjuvant COP plus PEG liposomal doxorubicin, regimen
ever reported to our knowledge to treat this tumor, and
the very good response at 5 years of follow-up show some
issues of interest.
A longer follow-up and further studies are warranted to
determine whether this combination treatment may be
useful in the management of FDC sarcoma, at least in
localized nodal disease, once it is identified and well char-
acterized by the appropriate application of immunohisto-
chemical staining.
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